Cynthia Turner
Gerontology · Monroe, LANPI 1033775184
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 9.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,876 and has fallen 88.2% since, to $221 in 2025.
Across 126 payments — averaging $38.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$483
- AstraZeneca$478
- Boston Scientific$382
- Amgen$377
- Johnson & Johnson$363
- Novartis$317
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,872100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 27 | $483 |
| AstraZeneca(2 entities) | 6 | $478 |
| Boston Scientific | 7 | $382 |
| Amgen | 8 | $377 |
| Johnson & Johnson | 10 | $363 |
| Novartis | 24 | $317 |
| Merck | 14 | $286 |
| Bayer | 3 | $241 |
| AbbVie | 2 | $206 |
| Sanofi | 2 | $200 |
| Gilead | 2 | $149 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Corium, LLC | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $124 |
| Abbott | 1 | $108 |
| Exact Sciences | 1 | $107 |
| Regeneron Healthcare Solutions, Inc. | 1 | $98 |
| Neurelis, Inc. | 1 | $87 |
| Alkermes, Inc. | 1 | $84 |
| GSK | 1 | $81 |
| Axsome Therapeutics, Inc. | 1 | $79 |
| Viiv Healthcare Company | 1 | $75 |
| Lexicon Pharmaceuticals, Inc. | 2 | $59 |
| Itamar Medical Inc | 1 | $57 |
| Evofem Biosciences, Inc. | 1 | $50 |
| Medline Industries LP | 1 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $27 |
| Pfizer | 1 | $24 |
| Novo Nordisk | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$249
- WaveWriter Alpha Prime 16$148
- Kerendia$125
- Azstarys$125
- VRAYLAR$125
- ULTOMIRIS$125
- VOQUEZNA$125
- REXULTI$124
- AIRSUPRA$124
- CEREZYME$124
- CERDELGA$124
- FABRAZYME$124
- FREESTYLE LIBRE 3$108
- Cologuard Collection Kit$107
How this compares
$4,872 in reported general payments places this provider in the 85th percentile of 64 gerontology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 173 | $161,950 |
| EliquisApixaban | 83 | $70,248 |
| JardianceEmpagliflozin | 21 | $15,904 |
| Repatha SureclickEvolocumab | 19 | $11,057 |
| Metoprolol Succinate | 106 | $799 |
| Ezetimibe | 32 | $618 |
| Spironolactone | 92 | $410 |
| Carvedilol | 90 | $397 |
| Atorvastatin Calcium | 63 | $375 |
| ClopidogrelClopidogrel Bisulfate | 31 | $304 |
| Digoxin | 20 | $266 |
| Rosuvastatin Calcium | 14 | $189 |
| Furosemide | 38 | $176 |
| Amlodipine Besylate | 30 | $102 |
| Lisinopril | 22 | $98 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $317 | $161,950173 claims |
| PfizerEliquis | $24 | $70,24883 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 64 gerontology providers in Louisiana.
Other gerontology in Monroe
- Katrina GipsonMonroe$6K
- Sierra NorwoodMonroe$680
- Victoria RandallMonroe$496
- Tiffany FrostMonroe$173
- Tommie NolanMonroe$117
- Marguerita GriffinMonroe$116
- Jodie HarrisonSlidell$12K
- Whitney StevensSlidell$10K
- Rebekah HendryBossier City$6K
- Jessica GaubertBaton Rouge$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.